Adarigiline
Adarigiline ( ) is a monoamine oxidase inhibitor (MAOI) that was never marketed.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Adarigiline ( ) is a monoamine oxidase inhibitor (MAOI) that was never marketed. It is specifically a monoamine oxidase B (MAO-B) inhibitor. This drug candidate was first described in 2009, in a patent assigned to Helicon Therapeutics.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372429390 under CC BY-SA 4.0; modifications have been made.